key: cord-0284375-oeul7dyl
authors: Jost, Marco; Jacobson, Amy N.; Hussmann, Jeffrey A.; Cirolia, Giana; Fischbach, Michael A.; Weissman, Jonathan S.
title: CRISPR-based functional genomics in human dendritic cells
date: 2020-12-22
journal: bioRxiv
DOI: 10.1101/2020.12.22.423985
sha: 2b462f19ee520aebfba9aa7c0b27e2b7017537c0
doc_id: 284375
cord_uid: oeul7dyl

Dendritic cells (DCs) regulate processes ranging from antitumor and antiviral immunity to host-microbe communication at mucosal surfaces. It remains difficult, however, to genetically manipulate human DCs, limiting our ability to probe how DCs elicit specific immune responses. Here, we develop a CRISPR/Cas9 genome editing method for human monocyte-derived DCs (moDCs) that mediates knockouts with a median efficiency of >93% across >300 genes. Using this method, we perform genetic screens in moDCs, identifying mechanisms by which DCs tune responses to lipopolysaccharides from the human microbiome. In addition, we reveal donor-specific responses to lipopolysaccharides, underscoring the importance of assessing immune phenotypes in donor-derived cells, and identify genes that control this specificity, highlighting the potential of our method to pinpoint determinants of inter-individual variation in immune responses. Our work sets the stage for a systematic dissection of the immune signaling at the host-microbiome interface and for targeted engineering of DCs for neoantigen vaccination.

To further establish if B. theta LPS is a mild agonist of TLR4 rather than an antagonist, 182 we turned to genetic engineering of B. theta LPS. LPSs of Bacteroidetes generally contain 183 pentaacylated, monophosphorylated lipid A as opposed to the hexaacylated, diphosphorylated 184 lipid A of Proteobacteria (Coats et al., 2011; Weintraub et al., 1989) , in addition to other 185 differences including lipid A acyl group structures and LPS glycan composition. A previous 186 study had established that B. theta LPS modified to contain pentaacylated, diphosphorylated lipid 187 A has increased capacity to stimulate TLR4 signaling via the endocytotic pathway (Tan et al., 188 2015) . Hypothesizing that B. theta lipid A further lacking an acyl group would resemble known 189 TLR4 antagonists (Golenbock et al., 1991) 

To determine if the difference in activity between B. theta LPS and E. coli LPS arises solely 200 from different capacity to activate TLR4, we tested how TLR4 knockout affects responses to 201 these two LPSs. TLR4 knockout moDCs did not secrete detectable amounts of TNF-α in 202 response to E. coli LPS but secreted substantial amounts of TNF-α in response to B. theta LPS, 203 corresponding to 30-50% of the levels secreted by moDCs with knockout of the neutral control 204 gene RPE65 ( To identify such additional receptors, we leveraged our moDC editing strategy to conduct 209 an arrayed genetic screen (Figure 3a ). We designed a focused library targeting ~300 genes 210 including known and predicted pattern recognition receptors and multiple nodes of signaling 211 pathways downstream of each receptor class (Methods). We targeted each gene with 2-3 212 sgRNAs whenever multiple unique sgRNAs could be designed, distributed over four 96-well 213 plates, each of which also included four types of controls ( in response to B. theta LPS was strongly reduced by knockouts in the TLR4 signaling pathway, 219

including TLR4 and its co-receptor MD2 (LY96), CD14 (which delivers LPS to TLR4 and 220 initiates TLR4 endocytosis (Zanoni et al., 2011) ), as well as genes involved in MYD88 signaling, 221 11 the branch of TRIF signaling involved in NF-κB activation, and the NF-κB factor RELA ( Figure  222 3c, Figure 3 -Figure Supplement 5a-c). Indeed, 8-9 of the 10 targeted genes in MYD88 223 signaling reduced TNF-α secretion for both donors. Other knockouts also caused expected 224 phenotypes; for example, moDCs with knockout of A20 (TNFAIP3), which inhibits LPS-and 225 TNF-α-induced NF-κB signaling, secreted more TNF-α (Figure 3c , Figure 3 - Figure  226 Supplement 5c). Thus, our genetic screen accurately captured the genetic requirements for the 227 response to B. theta LPS. 228

Although the results for the two donors were similar overall, we noticed several key 229 differences. Most prominently, knockouts of PTPN6 (SHP-1) and to a lesser extent IL10 230 increased TNF-α secretion in response to B. theta LPS in one donor ("donor i") but not the other 231 ("donor h"), suggesting that these factors can constitutively suppress TNF-α secretion in a 232 manner that differs among individuals ( Figure 3d ). Indeed, unedited moDCs from donor i 233 secreted less TNF-α in response to both B. theta LPS and E. coli LPS than those from donor h 234 ( Figure 3e ). Second, MYD88 signaling contributed particularly strongly to the response to B. 235 theta LPS for donor h: knockout of TIRAP, the TLR4-proximal adapter for MYD88 signaling 236 (Fitzgerald et al., 2001; Fitzgerald and Kagan, 2020) , induced the strongest decrease in TNF-α 237 secretion other than TNF itself. For donor i, TLR4 and the TRIF pathway contributed more 238 strongly to the response, as evidenced by strong decreases in TNF-α secretion upon knockout of 239 

We further investigated two specific observations. First, because TIRAP knockout caused 244 a larger decrease in TNF-α secretion than TLR4 knockout in donor h, we wondered if other TLRs 245 contributed to the response to B. theta LPS. We focused on TLR2, canonically known as a 246 receptor for lipopeptides and teichoic acids, because TLR2 knockout caused the next-strongest 247 decrease in TNF-α secretion among TLRs and because TLR2 has been implicated in the 248 response to non-proteobacterial LPSs (Di Lorenzo et al., 2020; Werts et al., 2001) , although 249 these claims remain controversial. Indeed, moDCs with simultaneous knockout of TLR4 and 250 Second, to analyze the interplay between PTPN6 and IL-10 in suppressing TNF-α 257 secretion in moDCs from donor i, we measured IL-10 levels in the same samples. The effects of 258 knockouts on TNF-α and IL-10 secretion were well-correlated, suggesting that TLR4 signaling 259 via the TRIF and MYD88 branches accounts for secretion of both TNF-α and IL-10. PTPN6 260 stood out as an exception: whereas PTPN6 knockout strongly increased TNF-α secretion, it 261 moderately decreased IL-10 secretion (Figure 3g ), suggesting either that IL-10 acts upstream of 262 PTPN6 in suppressing TNF-α secretion or that PTPN6 specifically inhibits production of TNF-α 263 and not IL-10. More broadly, these results demonstrate how combining our moDC editing 264 strategy with multiple readouts can increase the resolution in evaluating immune response 265 pathways. 266 13 267

In summary, we describe an efficient and flexible strategy to introduce knockouts in DCs derived 269 from human donors. Our strategy is compatible with diverse readouts, such as cytokine profiling, 270 RNA-seq, flow cytometry, and microscopy, and enables genetic screens at previously intractable 271 scales, transforming our ability to probe the roles of DCs in human biology. Using our strategy, 272 we derive three main conclusions regarding the recognition of LPSs from the human 273 microbiome. First, we observe a contribution of TLR2 to signaling by B. theta LPS, which could 274 result from either an intrinsic ability of B. theta LPS to bind both TLR4 and TLR2 or the 275 presence of contaminating TLR2 ligands in our B. theta LPS preparation. Although we cannot 276 rule out contamination, our observation is consistent with a recent report suggesting that B. More broadly, we find that human DCs initiate specific responses to LPS from 291 commensal Bacteroidetes, challenging the notion that these LPSs are innocuous components of 292 the human gut microbiota, as further evidenced by a recent report that homeostatic, TLR4-293 dependent induction of IFN-β by B. fragilis LPS contributes to antiviral immunity (Stefan et al., 294 2020 B. theta strains were stored at -80 °C in growth medium mixed in equal volume with 50% 334 glycerol in water. Strains were streaked from glycerol stocks onto BHI/blood agar using plastic 335 inoculating loops. Strains were allowed to grow 24-48 h in an anaerobic chamber. Single 336 colonies were used to inoculate 4 10-mL aliquots of supplemented BHI broth per strain, and after 337 24 h the 10-mL cultures were expanded to 1 L each in glass bottles, producing 4 L total culture 338 volume per strain. Cultures were allowed to grow to stationary phase (24-36 h) and were pelleted 339 at 3400 × g for 1 h at 4 °C. Pellets were washed in PBS and shipped frozen to the UCSD 340

GlycoAnalytics Core for LPS purification. Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA). Cell counts were 375 determined in duplicate using a Countess II automated hemocytometer (Thermo Fisher 376 Scientific). The isolated monocytes were cultured in complete RPMI medium, supplemented 377 with 50 ng/mL GM-CSF and 20 ng/mL IL-4 immediately prior to use, at a density of 1 · 10 6 to 378 18 1.3 · 10 6 per mL at 37 °C and 5% CO2 for 7 d. Medium was exchanged every two or three days 379 during this period (twice total). DCs on day 7 were generally positive for CD80, CD83, HLA-380 DR, CD11b, CD11c, and CD205 and expressed intermediate levels of CD86 CellStripper was performed for 5 min. The detached cells were combined, centrifuged at 100 × g 402 for 10 min, resuspended in RPMI medium, and combined with the non-attached cells. in 20 µL nucleofection solution P1 or P3 (with supplement added, Lonza) per 4 · 10 5 cells and 5 533 µL pre-formed RNP or nucleofector solution (no RNP control) was added. Immediately after 534 nucleofection, 75 µL pre-warmed complete RPMI medium supplemented with 50 ng/mL GM-535 CSF and 20 ng/mL IL-4 were added to each well without disturbing the cells by letting the 536 medium run down the side of the cuvette. After incubation at 37 °C and 5% CO2 for 1 h, the cells 537 were mixed by pipetting and then split into 2 wells of a flat-bottom 96-well plate filled with 50 538 25 µL pre-warmed complete RPMI medium supplemented with 50 ng/mL GM-CSF and 20 ng/mL 539 IL-4. The cells were incubated at 37 °C and 5% CO2 for 5 d, with medium replenished after 2 or 540 3 d and then used for assays. 541

The final electroporation condition (solution P3, pulse code DJ-108, 4 · 10 5 cells 542 electroporated with 10 pmol Cas9 and 25 pmol sgRNA) was obtained through iterative grid 543 searches of different conditions. In the process, several other conditions were also found to yield 544 good results, including nucleofection solution P1 with pulse code CB-128 (Figure 1 To determine the responses of cells to stimuli by ELISA, aliquots of cells were 565 transferred into flat bottom 96-well plates, diluted to 200 µL with complete RPMI medium 566 without cytokines, incubated at 37 °C and 5% CO2 for 2 -3 h, and stimulated as described 567

above. Each stimulation was performed in duplicate. Supernatants from stimulated cells were 568 harvested and used to measure TNF-α levels as described above. 569

For subsequent RNA isolation, aliquots containing 1 · 10 5 to 2.5 · 10 5 cells were 570 transferred into flat-bottom 24-well plates, diluted to 250 µL with complete RPMI medium 571 without cytokines, incubated at 37 °C and 5% CO2 for 2 -3 h, and stimulated as described 572 above. Each stimulation was performed in duplicate. RNA was extracted from treated cells as 573 described above. 574

During the incubation prior to stimulation, aliquots of the remaining cell suspension were 575 used to determine cell counts for each sample using a CellTiterGlo luminescence assay 576 (Promega, Madison, WI). Briefly, replicate aliquots of cells were transferred into an opaque flat-577 bottom 96-well plate, diluted to 100 µL, and incubated at 25 °C for 15 -30 min. After addition 578 of an equal volume of CellTiterGlo solution to each well, the plates were placed on an orbital 579 shaker for 2 min and then incubated at 25 °C for 10 min. Finally, luminescence in each well was 580 recorded using a GloMax Multi+ luminescence plate reader (Promega). For some experiments, 581 luminescence measurements from wells containing known numbers of unedited moDCs, as 582 determined using a Countess II automated hemocytometer (Thermo Fisher Scientific), were used 583 to calculate cell numbers for each sample. TNF-α secretion for each sample was then normalized 584 to cell numbers. For other experiments, TNF-α secretion was simply normalized to background-585 subtracted luminescence readings. In benchmark experiments, cell counts were also determined 586 by flow cytometry on an LSR-II flow cytometer (BD Bioscences) equipped with a 96-well 587 autosampler. Cell counts determined by flow cytometry and luminescence were well-correlated 588 ( Figure 1 -Figure Supplement 1a ) and all further cell counts were determined by luminscence. 589

To isolate genomic DNA from each sample for genotyping, aliquots of harvested moDCs 590 were transferred to a 96-well V-bottom plate, centrifuged at 300 × g for 10 min, and resuspended 591 in 50 µL QuickExtract DNA extraction solution (LuciGen, Middleton, WI). The suspensions 592 were transferred to 96-well PCR plates and incubated at 65 °C for 20 min and then at 98 °C for 5 593 min using a thermocycler. The extracted genomic DNA was stored at -30 °C until use. 594 595

Genomic regions surrounding each cut site were PCR-amplified using a 2-step protocol, largely 597 as described (Leenay et al., 2019) . Briefly, primer pairs were designed for each cut site using 598

Primer-BLAST (Ye et al., 2012) to amplify a 200-to 450-base pair region, ensuring that all cut 599 sites targeted by the pooled sgRNAs as well as a 50-base pair flanking region on each side of the 600 cut sites were included, with a targeted Tm of 60 °C. Constant adapters (forward: 5′-601 CTCTTTCCCTACACGACGCTCTTCCGATCT-3′; reverse: 5′-602 CTGGAGTTCAGACGTGTGCTCTTCCGATCT-3′) were appended to the designed primer 603 pairs. First-round PCRs of targeted sites were performed in 96-well format using at least 4,000 604 genomic copies for each sample, 0.5 µM of each primer, and Q5 Hot Start High-Fidelity 2x 605 master mix (NEB, Ipswich, MA) and the following protocol: 98 °C for 30 s; 35 cycles of 98 °C 606 for 10 s, 60 °C for 30 s, and 72 °C for 30 s; and a final extension at 72 °C for 2 min. Products 607 28 from the first PCR were diluted 1:100 in ddH2O and subjected to a second round of PCR using 608 the constant adapters as annealing sites, appending Illumina P5 and P7 adapters and two eight-609 base barcodes on both ends that together uniquely identified each sample. 12 cycles of PCR were 610 performed using the same conditions described above. After the second PCR, all samples were 611 pooled and the combined samples were purified using a 0.8x AMPure XP purification (Beckman 612

Coulter, Brea, CA). Final libraries were validated and quantified using the 2100 Bioanalyzer 613 (Agilent) using the High Sensitivity DNA kit (Agilent) and sequenced in a 600-cycle paired-end 614 run on a MiSeq Instrument (Illumina) using MiSeq v3 Reagent kits. 615

Sequencing data of editing outcomes were analyzed and quantified using knock-knock 616 v0.3 ( https://github.com/jeffhussmann/knock-knock ) (Canaj et al., 2019) . For a few loci, some 617 amplicons contained large deletions with boundaries >20 bp from an sgRNA cut site that were 618 classified as "large deletions" by knock-knock but likely instead reflect amplification of partially 619 complementary fragments, given in particular the rare occurrence of large deletions with 620 individual sgRNAs. To avoid overestimating editing efficiency, reads with at least one alignment 621 boundary >40 bp from an sgRNA cut site or both alignment boundaries >20 bp from sgRNA cut 622 sites were re-classified into the "malformed layout" category. For all experiments in which a 623 gene was targeted with multiple sgRNAs, sequencing counts were adjusted by the size difference 624 to the WT locus, using the following formula: 625

where count is the raw count, lWT the length in bp of the WT locus, and lread the length in bp of 627 the edited locus. See below for a description of how the coefficient was derived. individual amplicon was gel-purified and quantified using a Qubit Fluorometer (Thermo Fisher 650 Scientific). The five amplicons were then mixed into pools at 11 different molar ratios. For 651 increased accuracy, the abundance of each fragment in these pools was measured using the 2100 652 30 Bioanalyzer (Agilent) using the High Sensitivity DNA kit (Agilent). Each pool was then diluted 653

to 33 fM (about 20,000 template molecules per µL, equivalent to genomic DNA isolated from 654 10,000 cells) and 1 µL of diluted pool was used as template for the first-round PCR as described 655 above, using a primer pair complementary to the constant overhangs on each fragment, designed 656 with the same criteria as our other amplicon primers. The PCRs additionally contained 4 µL of 657 genomic DNA from unedited DCs as excess non-productive template. The remainder of the 658 sequencing library preparation was carried out as described above, with unique sequencing 659 indices appended to each pool in the second-round PCR. The final libraries were sequenced on a 660

MiSeq (Illumina) and counts for each fragment were determined by aligning reads to the 661 expected amplicons. 662

To infer observation efficiency (amplification + sequencing) for each fragment, we 663 reasoned that the starting and the final composition of the pool should be related by the specific 664 observation efficiency of each amplicon, which should shift the abundance of each fragment 665 based on its specific observation efficiency: 666

where mi is the measured fractional abundance, si the starting abundance, and ei the fragment-668 specific observation efficiency. Note that the equation takes this form because we can measure 669 only fractional rather than absolute abundances of each amplicon at the end; thus 670

To compute the efficiencies, we arbitrarily set the efficiency e of the 447 bp fragment (which 672 was included in all pools) to 1 (en = 1) and then solved the resulting linear equation system 673

to obtain the observation efficiencies (amplification + sequencing) ei for each fragment in each 676 pool. Because we expected per-cycle PCR amplification efficiency to be a major contributor to 677 these efficiencies, we compared log2 e to fragment size and found it to be linearly correlated 678 ( Figure 1 -Figure Supplement 2b ). We therefore estimated the contribution of each bp in size 679 difference to observation efficiency using a linear regression of log2 e against length in bp; we 680 used the slope of this regression to correct sequencing counts as described above. We note that 681 size bias appears to be less evident when small amplicons are already overrepresented in the 682 input ( For donor p, the RNA extraction for one replicate sample with knockout of RPE65 and treated 692 with 100 ng/mL B. theta LPS failed. Reads were aligned strand-specifically to the human 693 genome, gene counts were quantified, and differential gene expression analysis was conducted as 694 described above. Read coverage along transcripts was quantified using plastid (Dunn and 695

Weissman, 2016). All other analyses were performed in python3.6. 696 697 32

To select genes to target in our arrayed genetic screen, we first included all genes from the 699 following categories of pattern recognition receptors (PRRs): Toll-like receptors, NOD-like 700 receptors, RIG-I-like receptors, C-type lectin receptors, Galectins, and SIGLECs. We then 701 assembled a list of all genes encoding relevant signaling proteins downstream of these PRRs, 702

including immediate adaptor proteins, kinases and ubiquitin ligases, the downstream 703 transcription factors, as well a limited subset of effector cytokines and cytokine receptors. 704

Finally, we completed the gene list with additional genes of interest by surveying our RNA-seq 705 data from human moDCs for expressed potential pattern recognition receptors such as predicted 706 surface/membrane proteins, carbohydrate-binding proteins, and proteins containing a V-set 707 domain using searches for Pfam domains, and by browsing the list of genes with the GO term 708 "innate immune response" that we had not yet included. This process ultimately resulted in a list 709 of >400 genes. To narrow the list down to ~300 genes to enable screening in four 96-well plates, 710 we first eliminated pseudogenes and a few PRR-like genes with well-established functions. We 711 then eliminated many genes involved in linear signaling pathways while ensuring that each 712 pathway was targeted at multiple nodes in the final library. In total, we targeted 291 unique 713 genes of interest. 714

The library additionally included 4 classes of controls: 1) non-targeting negative controls; 715 2) neutral controls (targeting negative controls); 3) targeting positive controls; and 4) essential 716 controls. As non-targeting negative controls, we picked non-targeting negative controls #1 and 717 #2 from Synthego. As neutral controls, we selected 9 genes (CRX, KCNV1, TRHR, LALBA, 718 RPE65, F13B, OR2D2, OR51T1, TAS2R9) that are not expressed in moDCs, as assessed by our 719 RNA-seq data and non-essential in any cell type surveyed at the time (from Project Achilles) 720 33 (Tsherniak et al., 2017) , and for which some functional annotation existed such as tissue-specific 721 activity. These genes include olfactory and taste receptors as well as genes expressed only in 722 specific tissues such as the retinal pigment epithelium or the testes. As a targeting positive 723 control for TNF-α ELISA readout, we included TNF. As essential controls, we included the two For each screen, monocytes were isolated from 1.5 · 10 9 PBMCs (AllCells) from a single 741 healthy human donor and differentiated into moDCs as described above. Differentiated moDCs 742

were electroporated with sgRNAs in 96-well format as described above. Plates were staggered in 743 34 10 min intervals to minimize the amount of time cells spent in nucleofection solution and the 744 time delay between electroporation and addition of recovery media. On day 3 after 745 electroporation, 4 wells of cells containing no pulse/no RNP control cells were harvested to 746 assess responses of unedited cells to B. theta LPS and E. coli LPS and to determine an optimal B. 747 theta LPS concentration for treatment of edited cells (Figure 3e) . Maintenance, harvesting, and 748 counting of electroporated moDCs was performed as described above. Plates were staggered for 749 luminescence reads to keep incubation time with the luminescence substrate constant. All cells 750

were treated with 100 ng/mL B. theta LPS in a volume of 200 µL. Concentrations of TNF-α and 751 IL-10 in cell supernatants were determined by ELISA as described above. Plates were staggered 752 in 7 min intervals throughout the entire process to keep incubation times constant. 753

Log2 fold-changes in TNF-α or IL-10 secretion were calculated as follows: 754 1) ELISA absorbance values for each individual sample were background-corrected 755 using absorbance values from media-only wells. For the IL-10 ELISAs, background-756 corrected absorbance below 0 (recorded for four samples) were assigned the 757 background-corrected absorbance of the sample with the lowest value greater than 0. 758 2) Background-corrected absorbance values were normalized by the average 759 luminescence (average of two replicate measurements) for each cell sample to 760 calculate a cell count-normalized absorbance. 761

3) For each sample, the cell count-normalized absorbance was normalized to the median 762 cell count-normalized absorbance of all 9 neutral targeting controls on the same 96-763 well plate to calculate a fold-change in TNF-α secretion. Normalization was 764 performed by plate to normalize for any plate effects. 765 4) Fold-changes were log2 transformed to calculate log2 fold-changes in TNF-α 766 secretion. 767 5) Log2 fold changes of replicate treatments were averaged to calculate the average log2 768 fold change of each knockout population. Normality tests suggested that the log2 fold-769 changes were generally normally distributed, rationalizing the averaging of the log2-770 transformed values. 771

Raw and processed ELISA and cell count data are included in Supplementary File 3. 772

To assess editing efficiency at all loci, amplification primer design and sequencing 773 library preparation were streamlined to increase throughput. A first round of amplification 774 primers was designed using PrimerServer (Zhu et al., 2017) , which uses a combination of 775 primer3 and BLAST to predict amplification primers. Design criteria were: 1) amplification of a 776 200-to 450-base pair region, 2) inclusion of all cut sites targeted by the sgRNAs as well as a 35-777 base pair flanking region on each side of the cut sites was included, 3) ideal Tm of 60 °C. Design 778 criteria were successively relaxed if no primers matching these criteria were found, up to a 779 maximum amplicon size of 500 base pairs and a minimum flanking distance of 25 base pairs. 780 Primers containing overhangs as described above were ordered in 96-well format matching the 781 sgRNA layout and tested for efficient amplification of the targeted locus by amplifying genomic 782 DNA from unedited moDCs and sequencing the resulting amplicons on a MiSeq (Illumina), as 783 described above. For loci with inefficient amplification or a high fraction of off-target amplicons, 784 as assessed using knock-knock (Canaj et al., 2019, p.) , primers were designed using 785

PrimerBLAST (Ye et al., 2012) as described above, and efficient amplification confirmed by 786 sequencing. For some highly homologous locus pairs, such as SFTPA1/SFTPA2 and 787

LGALS7/LGALS7B, no primers could be designed that ensured completely unique amplification 788 

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in 979

A Subset of Polysaccharide 981 Capsules in the Human Symbiont Bacteroides thetaiotaomicron Promote Increased 982

Competitive Fitness in the Mouse Gut

The science and medicine of human immunology

CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in 988

Mature Primary Innate Immune Cells

Reprogramming human T cell function and specificity with non-viral genome 998 targeting

Efficient presentation of soluble antigen by cultured human 1000 dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus 1001 interleukin 4 and downregulated by tumor necrosis factor alpha

Genetic and evolutionary determinants of human 1004 population variation in immune responses

Generation of knock-in 1008 primary human T cells using Cas9 ribonucleoproteins

Genetic Modification of Dendritic Cells with RNAi

Cancer Vaccines: Methods and Protocols

Commensal Microbiota Modulation of 1015

Natural Resistance to Virus Infection

Weak Agonistic LPS Restores Intestinal

Immune Homeostasis

METHODS AND SYSTEMS FOR GUIDE RNA 1022 DESIGN AND USE

Dendritic Cell Subsets in Intestinal Immunity and 1024 Inflammation

Receptor 4 Endocytosis Reveal a Common Immune-Evasion Strategy Used by 1028

Defining a Cancer 1034

Microbiome LPS Immunogenicity Contributes to Autoimmunity in 1040

Dendritic 1042 cells in cancer immunology and immunotherapy

Structural 1045 characterization of the lipid A component of Bacteroides fragilis strain NCTC 9343 1046 lipopolysaccharide

Leptospiral 1051 lipopolysaccharide activates cells through a TLR2-dependent mechanism

An insider's perspective: Bacteroides as a window into the 1054

Role of Adaptor TRIF in the 1057

MyD88-Independent Toll-Like Receptor Signaling Pathway

A Novel Toll/IL-1 Receptor Domain-Containing Adapter That 1061

Preferentially Activates the IFN-β Promoter in the Toll-Like Receptor Signaling

Primer-1064 BLAST: A tool to design target-specific primers for polymerase chain reaction

CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4

PrimerServer: a high-1070 throughput primer design and specificity-checking platform

of each individual locus; the primers with the best discriminating power that fit all other design 789 criteria (amplicon size, Tm, distance from cut site) were chosen. All primers are listed in 790Supplementary File 1. 791Amplicon PCRs and sequencing sequencing library preparation were performed largely 792 as described above, with the following modifications: 1) PCRs were performed in 384-well 793 format; 2) first-round PCRs were set up using a Biomek FX liquid handling system with a 96-794 well head (Beckman Coulter); 3) first-round PCR products were diluted into Echo Qualified 384-795Well Polypropylene Microplates using the Biomek FX; 4) PCR mastermix for the second-round 796 PCR was dispensed into 384-well PCR plates using the Biomek FX; and 5) diluted first-round 797 PCR products and indexing PCR primers were dispensed into the 384-well PCR plate using an 798Echo 525 acoustic liquid handler (Labcyte, San Jose, CA). Purification and validation of 799 sequencing libraries, sequencing, classification of sequencing outcomes, and correction for 800 amplicon size were performed as described above. For donor h, a small set of samples did not 801 produce aligning sequencing reads in a first PCR attempt. These samples were repeated manually 802 as described above, after which all but one sample produced aligning sequencing reads. Only 803 successfully prepared samples were included for analysis. For donor i, the sequencing library 804 preparation was repeated independently for >200 loci, which produced near-identical results 805 (Figure 3 - Figure Supplement 4c) , validating that the sequencing library preparation strategy is 806 robust and reproducible and that size-dependent amplification efficiency is consistent across 807PCRs. Samples with >100 size-corrected on-target reads (generally corresponding to >500 raw 808 on-target reads) were included to estimate editing efficiencies. For some pairs of highly 809 homologous loci (e.g. SFTPA1 and SFTPA2), amplicons for both loci were detected with primer 810 pairs designed to amplify each individual locus because it was impossible to design completely 811 37 specific primer pairs with the criteria used. These amplicons were not excluded when calculating 812 editing efficiency, such that editing efficiency is slightly underestimated for these loci. Results 813 from outcome classification, after correction for size, are listed in Supplementary File 4. 814 815 Sample sizes and sample size estimation 816No sample-size calculation was performed in advance. All results were reproduced in cells from 817 multiple independent donors, following conventions of the field. Within independent 818 experiments, assays were performed in duplicate or triplicate following conventions of the field. 819 820

All main findings were derived from experiments with cells from at least 2 independent donors. 822The main hits from the genetic screen were validated in cells from 2 additional, independent 823 donors. All treatments were performed in duplicate for readout by ELISA and qPCR and in 824 duplicate or triplicate for readout by RNA-seq. Cell counts were generally conducted in 825 duplicate. Information on number of replicates is contained in the figure legends. 826